Andrew Senchak, DO
Otolaryngology · Plano, TXNPI 1295754497
Payments from drug & device makers
Across 36 payments — averaging $111.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1K
- Acclarent, Inc$1K
- Photonicare Inc$1K
- Amgen$240
- Regeneron Healthcare Solutions, Inc.$153
- Biohaven Pharmaceutical Holding Company Ltd.$142
- plus $298 from 9 others
What the payments were for
- Consulting fees$1,05026%
- Travel & lodging$1,05026%
- Food & beverage$89922%
- Gifts$40%
- Other$1,00125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 6 | $1,119 |
| Acclarent, Inc | 1 | $1,050 |
| Photonicare Inc | 1 | $1,001 |
| Amgen | 2 | $240 |
| Regeneron Healthcare Solutions, Inc. | 7 | $153 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $142 |
| Aerin Medical Inc. | 2 | $64 |
| Sanofi | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Merck | 1 | $27 |
| GSK | 1 | $22 |
| Pfizer | 1 | $21 |
| Medtronic | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACCLARENT Balloon Inflation Device$1,050
- OtoSight Middle Ear Scope$1,001
- AIMOVIG$240
- NURTEC ODT$125
How this compares
$4,004 in reported general payments places this provider in the 70th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 38 | $709 |
| Meclizine Hcl | 58 | $500 |
| Fluticasone Propionate | 40 | $479 |
| Pantoprazole Sodium | 53 | $410 |
| Montelukast Sodium | 44 | $331 |
| Ondansetron OdtOndansetron | 27 | $290 |
| Sumatriptan Succinate | 21 | $267 |
| Triamcinolone Acetonide | 28 | $186 |
| Methylprednisolone | 19 | $126 |
| Amitriptyline Hcl | 27 | $88 |
| Diazepam | 19 | $30 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Plano
- Laurence ChuAustin$37.4M
- Mark ZafereoHouston$7.8M
- Neil GrossHouston$1.5M
- Chad McDuffieFrisco$1.5M
- Ian AlexanderBoerne$999K
- Stephen LaiHouston$968K
- Benjamin CilentoSpring$963K
- Amber LuongHouston$793K
- Jeffrey RosenbloomSan Antonio$720K
- Masayoshi TakashimaHouston$644K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.